An observational study in Chronic Subdural Hematoma, sponsored by Carilion Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Carilion Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Hematoma, Subdural, Chronic with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Hematoma, Subdural, Chronic · United States.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 3rd registered.
113 studies on the registry are indexed under Hematoma, Subdural, Chronic; 50 are open to participants now.
Browse Hematoma, Subdural, Chronic studies →10 of the 22 studies in Hematoma, Subdural, Chronic with a site in United States are open now. Recruiting first, the newest first:
Arsenal Medical, Inc. · Sites in United States
Ages 18–90
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Lahey Clinic · Sites in United States
Ages 18+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 40–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hematoma, Subdural, Chronic studies recruiting now, 26 (72%) set no upper age limit and 1 (3%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 2014; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 210 across 20 observational studies indexed under Hematoma, Subdural, Chronic.
Median enrollment 40 across the 15 interventional studies, 100 across the 7 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Carilion Clinic is the lead sponsor of 76 studies on the registry; 16 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
Carilion Clinic has 2 studies filed under Hematoma, Subdural, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hematoma, Subdural, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214623Kaneka Medical America LLCProspective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy | 2026-11-30 |
| NCT06181994Montefiore Medical CenterMiddle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH) | 2026-12 |
| NCT07715656Lahey ClinicAssessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Hematoma, Subdural, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to reduce the recurrence rate of chronic subdural hematomas (CSDH) by manipulating the post-operative intravenous fluid use. The hypothesis relies on the relationship between osmolality and volume changes related to osmolality. We will be administering dextrose 5% in 1/4 normal saline (D5 1/4NS) post-operatively to induce brain expansion which can take up the residual CSDH space, to help reduce recurrence rate.
Chronic subdural hematoma (CSDH) is a neurological disease characterized by a collection of fluid, blood, and blood degradation matter between the arachnoid and dura mater in a well-developed membrane cavity. The presentation of this disease begins with minor head trauma and takes 4-7 weeks to become symptomatic.
One of the significant problems exists with CSDH is the rate of recurrence, which currently stands at a 7-30% rate worldwide. The recurrence of a CSDH is typically defined as the presence of residual or recurrent CSDH after the first resolution, leading to additional surgical intervention either within 3 months (early recurrence) or after 3 months (late recurrence). Additional surgical intervention (recurrence rate) is the outcome variable that our study will be looking at. Factors leading to persistent recurrence include age, use of anticoagulant therapy, volume of hematoma cavity, degree of midline shift on CT, presence of residual air post-operatively, and volume of residual hematoma fluid. The variability in surgeons' operative and post-operative care, which tries to address the multiple factors that lead to recurrence, illustrates the difficulty in trying to reduce postoperative recurrence. In fact, there is no postoperative standard of care. These variations in operative and postoperative care have yet to significantly decrease the recurrent rate of CSDH.
Given the health status and fragility of the patient population that is most commonly affected by CSDHs, and the inherent morbidity related to operating on this population, we hypothesize that D5 1/4NS can help mitigate the issue of residual/recurrence CSDH leading to subsequent surgeries. The fluid dynamics of D5 1/4NS have been studied and we can assume that it will facilitate brain re-expansion.
We will be recruiting patients (male, female; 18-60 years old) from our center, Carilion Roanoke Memorial Hospital, that have been diagnosed with CSDH necessitating burr-hole evacuation who fit our inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
Drug: Dextrose 5% W/ Sodium Chloride 0.225%
Drug page: GlucoseStudies of GlucoseGlucose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
Also known as: D5 1/4NS
Recurrence Rate
We will see how many patients who are treated with D5 1/4NS have a recurrent episode of CSDH after their post-operative treatment.
Time frame: Within 120 days (+/- 7 days) of their initial burr-hole surgery.
Rate of Volume Change of Residual CSDH Space
We will see how fast the brain volume expands after the administration of both NS and D5 1/4NS.
Time frame: 24 (+/- 6 hours) hours post-operative.
Plan to share: No
Started Jan 2019 (actual). Primary completion is estimated for Jan 2030, 131 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2022 → Jan 2030 and completion Jun 2022 → Jun 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carilion Clinic